Introduction: The "Invisible Barrier" Behind a $130B Market
According to IQVIA, the global CNS therapeutics market surpassed $130 billion in 2025, growing at a CAGR exceeding 6%. However, impurity profiling in this field faces hurdles far exceeding those of standard small molecules: the heightened risk of NDSRI genotoxic impurities from nitrogen-containing heterocycles (e.g., piperazines, piperidines); the high analytical bar for isotopic separation in deuterated molecules; and the sheer structural complexity and abundance of chiral centers, which complicate impurity deconvolution.
As your dedicated partner in pharmaceutical impurity standards, Sinco focuses this issue on critical CNS active ingredients. We feature comprehensive suites of reference standards—including Deubutafrazine, Trazodone, Mirogabalin, Flupentixol, and Lurasidone—backed by full compliance dossiers to support your impurity investigations with traceable, reliable references.
Spotlight: Featured Products of This Release
VMAT2 Inhibitor: Deubutafrazine Impurities
•Key Challenges: Separation and identification of deuterated analogs demand exceptional HPLC-MS sensitivity and resolution. The ether linkage within the tetrahydroisoquinoline core is prone to isomerization and degradation under acidic conditions, leading to complex degradation pathways.
•Sinco Solution: Coverage of 48 related impurities, supplied with complete structural elucidation packages. We provide compliant reference standards supporting trace impurity analysis and method validation for deuterated drug candidates. (Full impurity list available via "Read More" below.)
SARI Antidepressant: Trazodone Impurities
•Key Challenges: Significant risk of NDSRI formation at the polyamine moiety; sensitivity of the triazolopyridone core to oxidation results in a complex degradation profile; difficulties in characterizing salt forms and controlling purity of the multi-hydrochloride salt.
•Sinco Solution: Coverage of 73 related impurities, supported by full authoritative dossiers. We facilitate compliant NDSRI research and comprehensive characterization of multi-salt impurities. (Full impurity list available via "Read More" below.)
α₂δ Ligand: Mirogabalin Impurities
•Key Challenges: High reactivity and poor selectivity of intermediates during the synthesis of the bicyclo[3.2.0]heptane skeleton; risk of NDSRI genotoxic impurities from the secondary amine fragment—a key CMC review focus for regulatory agencies.
•Sinco Solution: Coverage of 89 related impurities, backed by full compliance dossiers to support NDSRI reference standard research and analytical method development. (Full impurity list available via "Read More" below.)
D₁/D₂ Antagonist: Flupentixol Impurities
•Key Challenges: NDSRI risk associated with the piperazine side chain; synthetic complexity introduced by trifluoromethyl groups; increased impurity profile complexity due to E/Z (cis/trans) isomerism.
•Sinco Solution: Coverage of 16 key impurities, provided with complete structural characterization packages to support NDSRI compliance studies and method validation. (Full impurity list available via "Read More" below.)
D₂/5-HT₂A/5-HT₇ Antagonist: Lurasidone Impurities
•Key Challenges: Complex impurity profile arising from multi-step amination condensations; high NDSRI risk at the piperazine ring (a key ICH M7/FDA focus); analytical bottlenecks in separating multiple chiral isomers.
•Sinco Solution: Coverage of 51 related impurities, supported by full authoritative dossiers (including COA, NMR, MS, HPLC). We provide compliant reference standards for NDSRI analytical method development and risk mitigation. (Full impurity list available via "Read More" below.)
Why Choose Sinco?
✅ Compliance Foundation: CQC Certification + Complete Structural Elucidation Packages ensuring data integrity.
✅ Independent Synthesis: Proprietary library of 30,000+ compounds; expertise in synthesizing challenging impurities.
✅ Efficient Delivery: 24-hour response time; In-stock items ship within 2–4 business days; Trusted by partners in 40 countries worldwide.
Explore More New Arrivals Below